An analysis from the Congressional Budget Office estimates that a patent law change sought by brand name pharmaceutical industry stakeholders would add $1.3 billion in costs over 10 years to the US health care system by delaying generic drugs’…
Sourced through Scoop.it from: www.pharmacytimes.com
Kenneth Carnesi holds a Juris Doctor degree from New York Law School and a Professional Certificate in International Banking from Harvard Law School. Kenneth Carnesi is the Director of Operations and Government Sales at Anaptyx LLC and sits on the Boards of The Lazarus Organization, Monkeetech LLC and MG Madison Phillips, Inc. Mr. Carnesi has also founded CICG - Carnesi International Consulting Group, a company specializing in strategy consulting to small to mid-size businesses.
Kenneth Carnesi 
Leave a comment